Full-Time

Vice President

Late-Stage Clinical Development

Confirmed live in the last 24 hours

4D Molecular Therapeutics

4D Molecular Therapeutics

201-500 employees

Develops gene therapies for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$354k - $447kAnnually

Senior, Expert

Oakland, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform

You match the following 4D Molecular Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • MD
  • Clinical training in Ophthalmology
  • Retina fellowship training a plus
  • Board Certification (or equivalent)
  • Minimum of 8 years of biopharma industry experience in drug development
  • Phase 3 experience in retinal disease(s)
  • Experience with NDA, BLA or MAA submission(s)
  • Experience with gene therapy, other areas of Drug Development and commercialization is a plus
  • Strong interpersonal skills and high emotional coefficient
  • Highly effective written and verbal communication skills
  • Excellent analytical, problem-solving and strategic planning skills
  • Up to date understanding of the ophthalmic competitive landscape with a focus on retina
  • Prior Late Stage Clinical Trial experience in Retina
  • Experience in participating or leading global regulatory interactions
  • Ability to understand and translate complex data to key messages
  • Ability to thrive in a fast-paced environment
  • Proven ability to prioritize effectively
  • Proven ability to plan and conduct clinical trials ensuring high-quality trial execution and results within established timelines
  • Demonstrated track record in working effectively in cross-functional teams and work streams (pharmacovigilance, biostatistics, clinical operations, and regulatory)
  • Track record of thinking strategically and executing to strategy
  • Demonstrated success in influencing colleagues and senior leaders in various departments
  • Experience building and leading teams and driving engagement in a matrixed environment
  • Attention to detail, internal drive to generate high-quality work, and sense of passion and urgency to achieve team and program goals
  • Able to ensure accountability
  • Able to manage conflict
  • Comfortable managing ambiguity
  • Strong clinical and scientific knowledge of ophthalmology (and retinal disease in particular)
  • Track record of developing talent
  • Record of cultivating and managing internal and external cross-functional collaborations
  • Demonstrates high integrity
  • Experience in successfully presenting and interacting with the Ophthalmic Retina Community and regulatory authorities in US, EU and APAC
  • Integrated understanding of FDA, EMA, ICH, and GCP guidelines
  • Prior interactions with FDA and EMA regulatory agencies is desirable.
Responsibilities
  • Lead the development of the Late Stage Ophthalmology Therapeutic Area Strategy in collaboration with cross functional partners (including but not limited to Commercial, CMC, Regulatory, and Early Research)
  • Implement Ophthalmology TA Strategy through phase 3 and phase 4 studies in the clinical development plans
  • Lead and manage a team of physicians and clinical scientists to design and execute the late stage clinical trials across the designated ophthalmic diseases in alignment with the Ophthalmology TA strategy
  • Provide Clinical Scientific Leadership to the study teams
  • Provide medical leadership for cross-functional internal workstreams including pharmacovigilance, biostatistics, clinical operations, regulatory affairs, etc.
  • Collaborate as appropriate with early research and other functions as appropriate to identify potential new targets for development in the treatment of ophthalmic diseases, which may include and not limited to due diligences and other strategic opportunities as needed
  • Provide oversight and lead late stage teams responsible for development plans, study protocols, amendments, ICFs, IBs, INDs, annual reports, CSRs, regulatory response documents and other regulatory submissions or documents as appropriate
  • Collaborate with pharmacovigilance in the analysis of clinical trial safety data
  • Collaborate closely with Clinical Operations and be accountable for clinical trial conduct and timelines for associated key deliverables
  • Lead the design and writing of clinical protocols and associated clinical documents contribute as an author with the writing of abstracts, posters and/or meeting presentations
  • Keep up to date with compliance, SOPs and adhere to ICH, GCP, and relevant regulatory guidelines
  • Provide medical leadership for internal audits and regulatory inspections
  • Assist in preparation of materials for Advisory Board meetings, BOD meetings, etc
  • Represent 4DMT and Lead interactions and collaborations with potential partners
  • Identify and establish collaborations where appropriate with clinicians in the Ophthalmology community
  • Represent the Ophthalmology Therapeutic Area with key external stakeholders, including patients and patient advocacy groups, external experts, investors, and the ophthalmic and biotech business communities
  • Travel Domestic and Internationally as required ~20%
Desired Qualifications
  • Retina fellowship training a plus
  • Experience with gene therapy, other areas of Drug Development and commercialization is a plus
  • Prior interactions with FDA and EMA regulatory agencies is desirable.
4D Molecular Therapeutics

4D Molecular Therapeutics

View

4D Molecular Therapeutics develops gene therapies aimed at treating serious genetic diseases by delivering specific genetic material to patients' cells. The company utilizes a unique technology called Therapeutic Vector Evolution to create adeno-associated virus (AAV) vectors, which act as delivery vehicles for therapeutic genes targeting affected cells in the body. Unlike many competitors, 4DMT focuses on precision medicine for genetic disorders, including cystic fibrosis, and emphasizes rigorous research and clinical trials to ensure the safety and effectiveness of its therapies. The company's goal is to commercialize these gene therapies through direct sales or partnerships with larger pharmaceutical firms, while also securing funding to support its research and development efforts.

Company Size

201-500

Company Stage

IPO

Total Funding

$170.2M

Headquarters

Emeryville, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • 4DMT secured a $962 million deal with Astellas for their vector technology.
  • Positive interim data from 4D-710 trials show promise for cystic fibrosis treatment.
  • Series C financing raised $75 million, boosting research and development capabilities.

What critics are saying

  • Public stock offering may dilute existing shareholders' equity, causing dissatisfaction.
  • Analysts cutting estimates suggest potential financial instability or unmet expectations.
  • Reliance on partnerships like Astellas poses risk if outcomes don't meet expectations.

What makes 4D Molecular Therapeutics unique

  • 4DMT uses proprietary Therapeutic Vector Evolution for advanced AAV vector creation.
  • Their focus is on gene therapies for serious genetic diseases like cystic fibrosis.
  • 4DMT's R100 vector technology efficiently targets retinal cells for eye disease treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

0%

2 year growth

4%
GlobeNewswire
Mar 28th, 2024
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

EMERYVILLE, Calif., March 28, 2024 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced an update on its regulatory interactions and development path for 4D-710, an aerosolized genetic medicine for the treatment of CF lung disease.

Benzinga
Feb 6th, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast

Monday, 4D Molecular Therapeutics FDMT-5.21%+ Free Alerts released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients.

GlobeNewswire
Feb 5th, 2024
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

4D Molecular Therapeutics announces proposed public offering of common stock.

Simply Wall St
Nov 12th, 2023
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) just released its quarterly report and things are looking bullish.

Fabry Disease News
Nov 3rd, 2023
4DMT, FDA agree to lift clinical hold on Fabry gene therapy 4D-310

To address this, 4DMT launched a single safety study involving nonhuman primates to evaluate 4D-310 combined with an immunosuppressive regimen using rituximab and sirolimus (R/S) to lower the risk of aHUS and toxicity-related side effects.